Published Medical Literature

Study Finds Racial Disparities in Treatment Patterns Among Patients With Multiple Myeloma

Can Lenalidomide Delay Disease Progression of Smoldering Multiple Myeloma?

Carfilzomib, Panobinostat, Dexamethasone: Novel Combination in Resistant Myeloma

How Does Facility and Provider Volume Impact Survival in Multiple Myeloma?

Comparing Health-Care Costs Across Lines of Therapy for Multiple Myeloma

Risk Assessment and Survival Prediction in Patients With Multiple Myeloma

Supportive Care for Older Adults With Myeloma: Underuse of Guideline Recommendations?

ASCT in Myeloma: Will It Be Transplanted by Other Treatments?

Serum Immune Marker and Progression From MGUS to Multiple Myeloma

Early-Phase Study of Iberdomide Plus Dexamethasone for Resistant Multiple Myeloma

Daratumumab and Lenalidomide/Dexamethasone in Multiple Myeloma MAIA Trial

Two Phase III Trials Evaluating Daratumumab-Based Therapies for Multiple Myeloma

More Precise Prognostic Index in Myeloma Relies Heavily on Cytogenetics

Carfilzomib-Based Therapy for Resistant Myeloma: Frailty Index and Outcomes

Pretreated Multiple Myeloma: Pomalidomide Plus Bortezomib/Dexamethasone

Pinpointing Best Dose of Immunotherapy (AMG 420) in Resistant Myeloma

Update on CART-BCMA Therapy for Resistant Multiple Myeloma

Selinexor Plus Low-Dose Dexamethasone for Refractory Multiple Myeloma

Combining PET-CT and Bone Marrow Assessment in Multiple Myeloma

CASSIOPEIA Trial: Daratumumab Combination Therapy for Newly Diagnosed Multiple Myeloma

Cardiovascular Adverse Events During Proteasome Inhibitor Therapy for Myeloma

Gait Speed and Grip Strength: Predictors of Outcome in Hematologic Malignancies?

Rare Case of Refractory Multiple Myeloma With Dura Mater Involvement

Phase I Study Findings With bb2121 in Resistant Myeloma

Is There a Role for Phytochemicals in the Treatment of Multiple Myeloma?

Current State of Carfilzomib Research for Resistant Multiple Myeloma

Purging Multiple Myeloma Cells Using Bortezomib and Lenalidomide

ABCG2 Polymorphisms in Multiple Myeloma

Potential of Targeting Adipocytes in Treatment of Myeloma

Salvage Autologous Stem Cell Transplantation for Multiple Myeloma: Patient-Reported Outcomes

Epigenetic Inhibitors in Multiple Myeloma Bone Disease: A New Frontier?

Multiple Myeloma and Cardiovascular Comorbidities

Combination Targeted Therapies Under Study in Myeloma

Prognostic Model for Transplant-Ineligible Patients With Multiple Myeloma

Newly Diagnosed Myeloma: Phase II Trial of Carfilzomib and Dexamethasone

Beyond Diagnostic Codes: A New Multiple Myeloma Algorithm

Novel Antibody-Drug Conjugate in Resistant Multiple Myeloma

Adding Cyclophosphamide to Lenalidomide/Dexamethasone in Resistant Myeloma

Bacteremia After Autologous Stem Cell Transplantation in Multiple Myeloma

Advancing Understanding of the Efficacy of Immunomodulatory Drugs in Myeloma

Gene Expression and Progression of Multiple Myeloma

ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide/Dexamethasone in Resistant Myeloma

Model for Collaborative Physician-Pharmacist Clinic in Multiple Myeloma

First-Line Treatment of Myeloma: Factors With Prognostic Value of Success

Lenalidomide Maintenance in Newly Diagnosed Patients: Myeloma XI Trial

Updated Results With Carfilzomib Triplet in Transplant-Eligible Patients With Myeloma

Cellular Therapy Targeting BCMA in Resistant Multiple Myeloma

Impact of Donor Clonal Hematopoiesis on Stem Cell Transplantation

Racial Disparities in Multiple Myeloma: Do Genomic Abnormalities Play a Role?

Frailty Index May Predict Survival in Newly Diagnosed Myeloma

Safety of Daratumumab in Relapsed or Refractory Multiple Myeloma

Novel Signaling Pathway: Route to Potential Therapy for Multiple Myeloma?

Access to Care: Thalidomide-Based Therapy in Multiple Myeloma

ELOQUENT-2 Trial: Long-Term Benefits of Triplet Therapy in Multiple Myeloma

Analysis of Bone Marrow Stromal Cells in Patients With Myeloma During Chemotherapy

Survival Benefits of Maintenance Therapies for Multiple Myeloma

Guidelines for Managing Clostridium Difficile Infection in Younger Transplant Recipients

End-of-Life Care After Allogeneic Hematopoietic Cell Transplantation

Investigating Link Between Cancer-Related Fatigue and Survival in Myeloma

Multiple Myeloma and Bone Metastases: Dosing Interval of Bone-Modifying Agents

Combination Therapy for Older Transplant-Ineligible Patients With Multiple Myeloma

Predictive Risk Factors for Outcome After Transplantation for Myeloma

Destabilizing NEK2 May Overcome Resistance to Treatment in Multiple Myeloma

Update on Reduced-Intensity Conditioning for Certain Hematologic Malignancies

Immunotherapy in Multiple Myeloma: Today and Tomorrow

Twice-Weekly Ixazomib May Benefit Some Patients With Newly Diagnosed Multiple Myeloma

Closer Look at Therapeutic Interventional Clinical Trials in Multiple Myeloma

Long-Term Outcomes Reported With Escalated Melphalan in Multiple Myeloma

Time to Myeloma Diagnosis: Room for Improvement

Is Stem Cell Transplant Still Relevant in Today’s Treatment of Multiple Myeloma?

Intensified Treatment Approach May Improve Survival in Some Patients With Myeloma

Carfilzomib in Resistant Myeloma: Once Weekly Versus Twice Weekly

Is Elotuzumab Monotherapy Beneficial in Patients With Smoldering Multiple Myeloma?

Novel Immunotherapy for Poor-Prognosis Relapsed Multiple Myeloma

PANORAMA-1 Trial in Multiple Myeloma: Patient-Reported Outcomes With Panobinostat

Noninterventional Study of Lenalidomide Plus Dexamethasone in Resistant Myeloma

New Research Finds Clues to Reducing Bortezomib-Linked Neuropathy

Addition of CAR T-Cell Therapy to Stem Cell Transplantation in Refractory Multiple Myeloma

How Closely Do Circulating Tumor Cells, Cell-Free DNA, and Bone Marrow Biopsies Agree?

Is Higher Body Mass Index a Risk Factor for Multiple Myeloma?

Potential of Folate-Targeted Therapies for Multiple Myeloma

Updated ASCO Guideline for Use of Bone-Modifying Agents in Multiple Myeloma

Is DCEP Chemotherapy a Viable Bridge to Definitive Therapy in Resistant Myeloma?

Screening Strategies in Individuals at Risk of Developing Multiple Myeloma

Are Recipients of Hematopoietic Cell Transplantation at Risk for Cognitive Decline?

Denosumab Versus Zoledronic Acid for Treating Myeloma With Bone Disease

Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma

ASPIRE Trial: Triplet Therapy in Relapsed or Refractory Multiple Myeloma

High-Dose Therapy Followed by Autologous Stem Cell Transplant for Multiple Myeloma

Considering Newer Agents in Managing Relapse in Resistant Myeloma

BCMA as a Therapeutic Target and Biomarker in Multiple Myeloma

Clinical Practice Update on Bone-Modifying Agents in Patients With Multiple Myeloma

Infection Prevention in Patients With Multiple Myeloma

Early Research Studies May Advance the Treatment of Multiple Myeloma

Carfilzomib and Cardiovascular Adverse Events in Patients With Multiple Myeloma

Novel Antibody Clone for Targeting Multiple Myeloma Cancer Cells

Survival and CRP Levels Prior to Transplantation in Patients With Multiple Myeloma

Novel Three-Part Treatment Sequence in High-Risk Multiple Myeloma

What Role, If Any, Does Obesity Play in MGUS and Multiple Myeloma?

Cost-Effectiveness Comparisons of Treatments for Heavily Pretreated Multiple Myeloma

Differences in Genetic Mutations in Blacks and Whites With Multiple Myeloma

Venetoclax Combination Therapy for Relapsed or Refractory Multiple Myeloma

Can Type of Myeloma Influence Response to Monoclonal Antibodies?

Multiple Myeloma Precancerous Disease and African Americans

Gene Signature in Predicting Response to Immunomodulatory Derivatives in Myeloma

Protein Kinases CK1-alpha and CK2 in Pathogenesis of Multiple Myeloma

Carfilzomib Versus Bortezomib in Relapsed or Refractory Multiple Myeloma

Prognostic Immune Biomarker in Newly Diagnosed Multiple Myeloma

Lenalidomide Maintenance After Transplantation in Multiple Myeloma

MRI Versus PET-CT in Symptomatic Patients With Multiple Myeloma

Bendamustine, Prednisone, and Bortezomib Treatment for Light Chain Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

Treatment Tolerability in Patients With Relapsed or Refractory Multiple Myeloma

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Induction and Maintenance Therapies With Bortezomib in Myeloma

Prognostic Impact of MRD-Negative Status in Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma